![Kristina Masson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 618 149 $ al 31/05/2026
Kristina Masson is the founder of Acrivon Therapeutics, Inc., founded in 2018, and holds the title of Director & Executive VP-Business Operations since 2022.
Dr. Masson completed graduate and doctorate degrees at the University of Lund.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 21/05/2026 | 386.343 ( 0,9 % ) | 618 149 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Fundador | 01/03/2018 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
University of Lund
 University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Acrivon Therapeutics, Inc.
 Acrivon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops and sells precision oncology medicines | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
